Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patientswith acute migraine

Citation
B. Gomez-mancilla et al., Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patientswith acute migraine, CEPHALALGIA, 21(7), 2001, pp. 727-732
Citations number
33
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Neurology,"Neurosciences & Behavoir
Journal title
CEPHALALGIA
ISSN journal
0333-1024 → ACNP
Volume
21
Issue
7
Year of publication
2001
Pages
727 - 732
Database
ISI
SICI code
0333-1024(200109)21:7<727:SAEOPA>2.0.ZU;2-P
Abstract
In this randomized, double-blind, placebo-controlled, parallel-group study, patients received a single 50-mg oral dose of a 5-HT1D agonist, PNU-142633 (n = 34), or matching placebo (n = 35) during an acute migraine attack. No statistically significant treatment effects were observed at 1 and 2 h aft er dosing, even after stratifying by baseline headache intensity. At I and 2 h post-dose, 8.8% and 29.4% of the PNU-142633 group, respectively, and 8. 6% and 40.0% of the placebo group, respectively, experienced headache relie f; 2.9% and 8.8% of the PNU-142633 group and 0% and 5.7% of the placebo gro up were free of headache pain. Adverse events associated with PNU-142633 tr eatment included chest pain (two patients) and QTc prolongation (three pati ents). Results from this study suggest that anti-migraine efficacy is not m ediated solely through the 5-HT1D receptor subtype, although this receptor may contribute, at least in part, to the adverse cardiovascular effects obs erved with 5-HT agonist medications.